Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS | Embrace the transformative power of multimodal ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

Hey, AbbVie, what do you say? The Cubs are gonna strike out cancer today. | A new partnership between the Chicago-based ...

In the wake of sweeping cuts at the FDA’s Office of Prescription Drug Promotion (OPDP), Sen. | In the wake of sweeping cuts ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

Astellas is banging the drum for patient advocacy organizations (PAOs) again. | Astellas is banging the drum for patient ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy.

From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO ...